TLDR:
Regeneron Ventures, a Greenwich-based biotech venture capital fund, has launched with a $500 million commitment from Regeneron Pharmaceuticals. The fund will focus on investing in biopharmaceutical, health care, and health technology companies.
Key Points:
- Regeneron Ventures launched with a $500 million commitment from Regeneron Pharmaceuticals.
- The fund will be managed by former Regeneron Pharmaceuticals’ executives Dr. Michael Aberman and Dr. Jay S. Markowitz.
Regeneron Ventures, led by Aberman and Markowitz, aims to invest in promising companies in the biopharmaceutical, health care, and health technology sectors. With a focus on groundbreaking advancements, the fund will support long-term investments in innovative science and medicine. Both executives bring significant experience in the biotech industry, with Aberman previously serving as CEO of XenImmune Therapeutics and Markowitz as a senior partner at ARCH Venture Partners.
Overall, the launch of Regeneron Ventures signals a significant investment in the biotech industry, with a focus on fostering innovation and supporting the next generation of biotech companies.
